Kee Hung Chu

Keine laufenden Positionen mehr

78 Jahre

Consumer Services

Distribution Services

Health Technology

Profil

Kee Hung Chu served as an Executive Director, Chief Scientific Officer & VP at CK Life Sciences International (Holdings), Inc. from 2001 to 2018.
Prior to that, he was a Director at WEX Pharmaceuticals, Inc. from 2009 to 2011.
Chu holds a graduate degree and a doctorate from the University of California, Berkeley, and an undergraduate degree from The Chinese University of Hong Kong.

Ehemalige bekannte Positionen von Kee Hung Chu

Unternehmen	Position	Ende
WEX Pharmaceuticals, Inc. WEX Pharmaceuticals, Inc. Medical DistributorsDistribution Services WEX Pharmaceuticals, Inc. develops, manufactures, and sells pharmaceutical products for pain management. The pain management solutions are provided through its proprietary platform technology based on TTX (Tetrodotoxin). It owns and operates its research, development and manufacturing facilities in China through its subsidiaries. The company was founded on June 3, 1987 and is headquartered in Vancouver, Canada.	Direktor/Vorstandsmitglied	01.05.2011
CK LIFE SCIENCES INT'L., (HOLDINGS) INC.	Technik-/Wissenschafts-/F&E-Leiter	15.11.2018

Sehen Sie sich die Erfahrung von Kee Hung Chu im Detail an

Ausbildung von Kee Hung Chu

The Chinese University of Hong Kong	Undergraduate Degree
University of California, Berkeley	Doctorate Degree

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Kee Hung Chu im Detail an

Beziehungen

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Börsennotierte Unternehmen	1
CK LIFE SCIENCES INT'L., (HOLDINGS) INC.	Health Technology

Private Unternehmen	1
WEX Pharmaceuticals, Inc. WEX Pharmaceuticals, Inc. Medical DistributorsDistribution Services WEX Pharmaceuticals, Inc. develops, manufactures, and sells pharmaceutical products for pain management. The pain management solutions are provided through its proprietary platform technology based on TTX (Tetrodotoxin). It owns and operates its research, development and manufacturing facilities in China through its subsidiaries. The company was founded on June 3, 1987 and is headquartered in Vancouver, Canada.	Distribution Services